The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 08, 2020
Filed:
Aug. 11, 2015
Applicant:
Imclone, Llc, Indianapolis, IN (US);
Inventors:
Paolo B. Abada, Indianapolis, IN (US);
Shao-Chun Chang, Carmel, IN (US);
Yanzhi Hsu, Basking Ridge, NJ (US);
Ling Yang, Bridgewater, NJ (US);
Assignee:
ImClone LLC, Indianapolis, IN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61P 35/00 (2018.01); G01N 33/57438 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); G01N 2333/47 (2013.01); G01N 2800/52 (2013.01);
Abstract
The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.